Amgen Inc (OQ:AMGN)

May 02, 2024 04:01 pm ET
AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
THOUSAND OAKS, Calif., May 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024.
May 01, 2024 07:00 am ET
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
Findings From Tezspire® (tezepelumab-ekko) Phase 2a COURSE COPD Study
Apr 29, 2024 04:00 pm ET
AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif., April 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
Apr 26, 2024 09:00 am ET
AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
THOUSAND OAKS, Calif., April 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating and potentially vision-threatening autoimmune disease that can cause proptosis (eye bulging), diplopia (double vision), eye pain, redness and swell
Apr 16, 2024 05:26 pm ET
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
Planning Underway for Phase 3 Development of Tezepelumab in COPD  
Feb 26, 2024 08:00 am ET
AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO
THOUSAND OAKS, Calif., Feb. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the opening of its manufacturing site in Central Ohio, the newest in its global operations network and the most advanced facility to date.
Feb 19, 2024 03:00 pm ET
AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE
THOUSAND OAKS, Calif., Feb. 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline. Murdo Gordon, executive vice president of Global Commercial Operations at Amgen, Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, Vikram Karnani, executive vice president of Global Commercial Operations and Medical Aff
Feb 09, 2024 03:00 pm ET
AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
THOUSAND OAKS, Calif., Feb. 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m. ET on Wednesday, Feb. 14, 2024. Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, Murdo Gordon, executive vice president of Global Commerical Operations at Amgen, and Susan Sweeney, senior vice president of Global Marketing, Access and Capabilities at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available t
Feb 06, 2024 03:01 pm ET
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
THOUSAND OAKS, Calif., Feb. 6, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2023 versus comparable periods in 2022.
Feb 01, 2024 03:00 pm ET
AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
THOUSAND OAKS, Calif., Feb. 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
Jan 29, 2024 04:00 am ET
deCODE genetics: A sequence variant that increases risk of pregnancy loss
REYKJAVIK, Iceland, Jan. 29, 2024 /CNW/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Iceland, Denmark, and the USA published a study today in Nature Structural & Molecular Biology titled "Variant in the synaptonemal complex protein SYCE2 associates with pregnancy loss through effects on recombination".
Jan 29, 2024 04:00 am ET
deCODE genetics: A sequence variant that increases risk of pregnancy loss
REYKJAVIK, Iceland, Jan. 29, 2024 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Iceland, Denmark, and the USA published a study today in Nature Structural & Molecular Biology titled "Variant in the synaptonemal complex protein SYCE2 associates with pregnancy loss through effects on recombination".
Jan 09, 2024 10:25 am ET
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
FN Media Group News Commentary - According to the report titled "Aging in the United States," published by the Population Reference Bureau, "the number of Americans aged 65 and older is projected to increase more than double over 95 million by the...
Jan 03, 2024 03:00 pm ET
AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., Jan. 3, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Monday, January 8, 2024. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
Dec 26, 2023 08:00 am ET
Dec 14, 2023 08:00 am ET
AMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION
James Bradner, M.D., Joins as Executive Vice President, Research and Development, and Chief Scientific Officer
Dec 14, 2023 04:00 am ET
AMGEN TO SPONSOR THE IRISH OPEN
Sponsorship of the Golf Event Continues Following Horizon Acquisition
Dec 13, 2023 03:00 pm ET
FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer
Currently There are no Approved Therapeutic Options for Third-Line Treatment of Advanced SCLC1
Dec 12, 2023 03:00 pm ET
AMGEN ANNOUNCES 2024 FIRST QUARTER DIVIDEND INCREASE TO $2.25 PER SHARE
THOUSAND OAKS, Calif., Dec. 12, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the first quarter of 2024. This is the 12th consecutive year that Amgen has increased its dividend and comes as the Company continues to invest in innovation and deleverage its balance sheet. The dividend will be paid on March 7, 2024, to all stockholders of record as of the close of business on February 16, 2024.
Dec 08, 2023 08:00 am ET
AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023
Multiple Investigator Sponsored Studies Support the Potential of BLINCYTO® (blinatumomab) Across Acute Lymphoblastic Leukemia Treatment Paradigm
Nov 22, 2023 03:00 pm ET
AMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE
THOUSAND OAKS, Calif., Nov. 22, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 9:10 a.m. EST on Wednesday, Nov. 29, 2023. Peter H. Griffith, executive vice president and chief financial officer at Amgen, and Paul Burton, senior vice president and chief medical officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
Nov 10, 2023 08:00 am ET
AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023
New Repatha® (evolocumab) Data Show No Decline in Cognitive Function Associated With Very Low Levels of LDL-C
Nov 07, 2023 03:05 pm ET
AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023
FOREMOST Study Finds Oral Otezla® (apremilast) Significantly Improved Disease Control vs. Placebo
Nov 07, 2023 03:00 pm ET
AMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023
First Phase 2 Trial in Sjögren's to Achieve the Primary Endpoint Both in Patients With Severe Symptomatology and Those With Systemic Disease
Nov 02, 2023 08:00 am ET
AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)
THOUSAND OAKS, Calif., Nov. 2, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data for KRYSTEXXA® (pegloticase) showing a decrease in blood pressure during treatment of adults living with chronic gout refractory to oral urate-lowering treatment − uncontrolled gout − both with and without chronic kidney disease (CKD). The data will be presented at the American Society of Nephrology Kidney Week, taking place Nov. 2-5, in Philadelphia.
Nov 01, 2023 09:00 am ET
AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO
Breadth of Research Reflects Amgen's Commitment to Rheumatology
Oct 31, 2023 07:00 am ET
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif., Oct. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 20231.
Oct 25, 2023 04:00 pm ET
AMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif., Oct. 25, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Tuesday, October 31, 2023, before the opening of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 5:00 a.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
Oct 24, 2023 04:00 pm ET
AMGEN ANNOUNCES 2023 FOURTH QUARTER DIVIDEND
THOUSAND OAKS, Calif., Oct. 24, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the fourth quarter of 2023. The dividend will be paid on December 8, 2023, to all stockholders of record as of the close of business on November 17, 2023.
Oct 22, 2023 10:30 am ET
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
First Global Phase 3 Study in Patients with Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer
Oct 20, 2023 08:00 am ET
AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER
Tarlatamab Delivered an Encouraging Objective Response Rate of 40% and Median Overall Survival of 14.3 Months in Patients with Advanced SCLC
Oct 19, 2023 04:00 pm ET
AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023
THOUSAND OAKS, Calif., Oct. 19, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will host a webcasted call for the investment community at 8:00 a.m. ET on Tuesday, Oct. 24, 2023 following the presentation of new data from Amgen's innovative oncology portfolio including AMG 193 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 and data from tarlatamab, xaluritamig, and LUMAKRAS® (sotorasib) that will be presented at the European Society for Medical Oncology (ESMO) Congress 2023. David M. Reese, M.D., executive vice president of R
Oct 16, 2023 09:00 am ET
AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023
Results From Phase 2 DeLLphi-301 Trial Highlight Potential of Tarlatamab, First BiTE in Patients With Previously Treated SCLC
Oct 12, 2023 09:00 am ET
Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell...
Oct 06, 2023 08:30 am ET
AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC
Advances Amgen's Mission to Serve Patients With First-in-Class Rare Disease Medicines
Oct 04, 2023 11:00 am ET
Large-scale proteomics in population-based studies from UK and Iceland
REYKJAVIK, Iceland, Oct. 4, 2023 /CNW/ -- In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods. They analyzed the proteins in the context of diseases and diversity in the sequence of the genome and compared measurements made using two platforms of thousands of proteins in samples from large groups from the UK Biobank and Iceland.
Oct 04, 2023 11:00 am ET
Large-scale proteomics in population-based studies from UK and Iceland
REYKJAVIK, Iceland, Oct. 4, 2023 /PRNewswire/ -- In a paper released today, deCODE Genetics' scientists shared their findings from a plasma proteomics study performed using affinity-based methods. They analyzed the proteins in the context of diseases and diversity in the sequence of the genome and compared measurements made using two platforms of thousands of proteins in samples from large groups from the UK Biobank and Iceland.
Sep 20, 2023 04:00 pm ET
AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS
Network Aims to Advance Collaboration Across Industry and Academia to Accelerate Treatment Development for Patients
Sep 20, 2023 01:16 pm ET
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Amgen Inc’s Directors and Officers for Breach of Fiduciary Duties – AMGN
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Amgen Inc. (“Amgen”) (NASDAQ: AMGN) breached their fiduciary duties to...
Sep 11, 2023 04:00 pm ET
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., Sept. 11, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:40 a.m. BST on Thursday, Sept. 14, 2023. Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
Sep 10, 2023 09:00 am ET
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC
In Phase 1b Study, Patients Treated in First-Line Demonstrated a Confirmed Objective Response Rate of 65%
Sep 01, 2023 09:20 am ET
Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen’s acquisition of Horizon.
Aug 11, 2023 08:00 am ET
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Amgen Inc’s Directors and Officers for Breach of Fiduciary Duties – AMGN
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Amgen Inc. (“Amgen”) (NASDAQ: AMGN) breached their fiduciary duties to...
Aug 01, 2023 04:00 pm ET
AMGEN ANNOUNCES 2023 THIRD QUARTER DIVIDEND
THOUSAND OAKS, Calif., Aug. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the third quarter of 2023. The dividend will be paid on September 8, 2023, to all stockholders of record as of the close of business on August 18, 2023.
Jul 31, 2023 04:00 pm ET
AMGEN ANNOUNCES WEBCAST OF 2023 SECOND QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif., July 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Thursday, August 3, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 1:30 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
Jul 27, 2023 06:15 pm ET
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Amgen Inc’s Directors and Officers for Breach of Fiduciary Duties – AMGN
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Amgen Inc. (“Amgen”) (NASDAQ: AMGN) breached their fiduciary duties to Amgen and its shareholders. If you are an Amgen shareh
Jul 14, 2023 03:59 pm ET
MOORE KUEHN ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM
NEW YORK, July 14, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against:
Jun 09, 2023 04:00 pm ET
AMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., June 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 44th Annual Global Healthcare Conference at 2:20 p.m. ET on Wednesday, June 14, 2023. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors, and the general public.
Jun 04, 2023 08:00 am ET
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023
LUMAKRAS ® (sotorasib) Demonstrated Delayed Time to CNS Progression, Longer CNS PFS and Higher Intracranial ORR vs Docetaxel in Post-Hoc Analysis of Phase 3 CodeBreaK 200 Trial
Jun 01, 2023 09:00 am ET
AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023
New LUMAKRAS® (sotorasib) Data From First Study Evaluating Intracranial Efficacy of a KRAS G12C Inhibitor Versus Docetaxel in Treated KRAS G12C-Mutated Advanced NSCLC
May 30, 2023 06:00 pm ET
AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023
MOSAIC Study is First to use MRI to Assess Inflammation in Peripheral Joints and Entheses in Psoriatic Arthritis Patients
May 26, 2023 04:00 pm ET
AMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT
THOUSAND OAKS, Calif., May 26, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. ET on Wednesday, May 31, 2023. David M. Reese, M.D., executive vice president of Research and Development at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
May 16, 2023 11:31 am ET
AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS
THOUSAND OAKS, Calif., May 16, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement in response to the U.S. Federal Trade Commission's (FTC) complaint seeking to block the company's proposed acquisition of Horizon Therapeutics plc:
May 12, 2023 07:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN
Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. (“Amgen” or the “Company”) (NASDAQ: AMGN).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980. The...
May 12, 2023 01:14 pm ET
AMGN LAWSUIT ALERT: Levi & Korsinsky Notifies Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected...
May 12, 2023 05:45 am ET
AMGN SHAREHOLDER ALERT: Jakubowitz Law Reminds Amgen Shareholders of a Lead Plaintiff Deadline of May 12, 2023
NEW YORK, May 12, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN).
May 11, 2023 01:02 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Amgen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 12, 2023 – (NASDAQ: AMGN)
The Gross Law Firm issues the following notice to shareholders of Amgen Inc.. Shareholders who purchased shares of AMGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as...
May 11, 2023 12:30 pm ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc. (AMGN)
The Law Offices of Frank R. Cruz reminds investors of the upcoming May 12, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Amgen Inc. (“Amgen” or the “Company”) (NASDAQ:
May 11, 2023 09:02 am ET
AMGN Final Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed against Amgen Inc. (AMGN)
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. (“Amgen”)...
May 11, 2023 05:45 am ET
AMGN LAWSUIT ALERT: Levi & Korsinsky Notifies Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, May 11, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit.
May 10, 2023 09:00 pm ET
AMGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Amgen Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Amgen Inc. (“Amgen” or the “Company”) (NASDAQ: AMGN) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Amgen securities between July 29, 2020 and April 27, 2022, both dates inclusive (the “Class Period”). Investors have until May 12, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
May 10, 2023 08:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN
NEW YORK, May 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
May 10, 2023 01:01 pm ET
AMGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 12, 2023 in the Class Action Filed on Behalf of Amgen Inc. Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN) alleging that the Company violated federal securities laws. This lawsuit is on behalf of all persons who purchased or...
May 10, 2023 10:30 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc. (AMGN)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 12, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Amgen Inc. (“Amgen” or the “Company”)...
May 10, 2023 09:46 am ET
AMGN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Amgen Inc. (AMGN) Shareholders of Securities Fraud Class Action Lawsuit
RADNOR, Pa., May 10, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ("Amgen") (NASDAQ: AMGN). The action charges Amgen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.  As a result of Amgen's materially misleading statements and omissions to the public, Amgen's investors
May 10, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Amgen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 12, 2023 - (NASDAQ: AMGN)
NEW YORK, May 10, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Amgen Inc..
May 09, 2023 11:30 pm ET
Amgen Inc.: Please contact the Portnoy Law Firm to recover your losses; May 2, 2023 deadline
The Portnoy Law Firm advises Amgen Inc. (NASDAQ: AMGN) investors that a lawsuit filed on behalf of investors that purchased Amgen securities (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, inclusive (the “Class Period”). Investors are...
May 09, 2023 09:00 am ET
AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE
Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities
May 09, 2023 09:00 am ET
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan’s proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with...
May 09, 2023 05:45 am ET
AMGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 12, 2023 in the Class Action Filed on Behalf of Amgen Inc. Shareholders
NEW YORK, May 9, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN) alleging that the Company violated federal securities laws.
May 08, 2023 09:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of SVB Financial Group (NASDAQ: SIVB, SIVBP), Amgen Inc. (NASDAQ: AMGN), and...
May 08, 2023 04:45 pm ET
DEADLINE ALERT for SIVBQ, AMGN, SBNY/SBNYP, and GOOG/GOOGL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
May 08, 2023 12:30 pm ET
AMGN LAWSUIT ALERT: Levi & Korsinsky Notifies Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected...
May 08, 2023 10:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Amgen Inc. (AMGN) Investors of Class Action and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) and certain of its officers, on behalf of all persons and entities...
May 08, 2023 09:00 am ET
AMGN Investors Have Opportunity to Lead Amgen Inc. Securities Fraud Lawsuit
BENSALEM, Pa., May 8, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN).
May 08, 2023 09:00 am ET
NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE
Real World Evidence Study Showed use of Prolia Reduced Fracture Risk in Postmenopausal Women With Osteoporosis Versus Alendronate Treatment
May 08, 2023 08:15 am ET
AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amgen In
Did you lose money on investments in Amgen Inc.? If so, please visit Amgen Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
May 08, 2023 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Amgen Investors of a Lead Plaintiff Deadline of May 12, 2023
NEW YORK, May 8, 2023 /PRNewswire/ -- Attention Amgen Inc. ("Amgen") (NASDAQ: AMGN) shareholders:
May 06, 2023 07:00 am ET
AMGEN SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amgen To Contact Him Directly To Discuss Their Options
NEW YORK, May 6, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amgen, Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) and reminds investors of the May 12, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
May 05, 2023 04:27 pm ET
AMGN NOTICE: TOP RANKED ROSEN LAW FIRM Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action – AMGN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the “Class Period”), of the important May 12, 2023 lead plaintiff...
May 05, 2023 03:03 pm ET
AMGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 12, 2023 in the Class Action Filed on Behalf of Amgen Inc. Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN) alleging that the Company violated federal securities laws. This lawsuit is on behalf of all persons who purchased...
May 05, 2023 10:30 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc. (AMGN)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 12, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Amgen Inc. (“Amgen” or the “Company”)...
May 05, 2023 05:45 am ET
AMGN SHAREHOLDER ALERT: Jakubowitz Law Reminds Amgen Shareholders of a Lead Plaintiff Deadline of May 12, 2023
NEW YORK, May 5, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN).
May 04, 2023 10:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN
Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. (“Amgen” or the “Company”) (NASDAQ: AMGN).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980. The...
May 04, 2023 10:30 am ET
AMGN Investors Have Opportunity to Lead Amgen Inc. Securities Fraud Lawsuit
LOS ANGELES, May 4, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN).
May 04, 2023 05:45 am ET
AMGN LAWSUIT ALERT: Levi & Korsinsky Notifies Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, May 4, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit.
May 03, 2023 09:30 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of SVB Financial Group (OTC: SIVPQ, SIVBQ), Amgen Inc. (NASDAQ: AMGN), and...
May 03, 2023 05:53 pm ET
AMGN SHAREHOLDER ALERT: Jakubowitz Law Reminds Amgen Shareholders of a Lead Plaintiff Deadline of May 12, 2023
Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN). To receive updates on the lawsuit, fill out the...
May 03, 2023 04:00 pm ET
AMGEN TO PRESENT AT THE 2023 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., May 3, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2023 Bank of America Merrill Lynch Global Healthcare Conference at 11:00 a.m. ET on Tuesday, May 9, 2023. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
May 03, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Amgen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 12, 2023 - (NASDAQ: AMGN)
NEW YORK, May 3, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Amgen Inc..
May 03, 2023 12:55 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN
NEW YORK, May 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
May 02, 2023 03:30 pm ET
AMGN LAWSUIT ALERT: Levi & Korsinsky Reminds Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected...
May 02, 2023 12:00 pm ET
AMGN Investors Have Opportunity to Lead Amgen Inc. Securities Fraud Lawsuit
LOS ANGELES , May 2, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN).
May 02, 2023 05:45 am ET
AMGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 12, 2023 in the Class Action Filed on Behalf of Amgen Inc. Shareholders
NEW YORK, May 2, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN) alleging that the Company violated federal securities laws.
May 01, 2023 03:56 pm ET
AMGEN DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Amgen Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Con
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. (“Amgen”)...
May 01, 2023 11:43 am ET
DEADLINE ALERT for SIVB, AMGN, SBNY/SBNYP, and GOOG/GOOGL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 01, 2023 10:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Amgen Inc. (AMGN) Investors of Class Action and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) and certain of its officers, on behalf of all persons and entities...
May 01, 2023 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Amgen Investors of a Lead Plaintiff Deadline of May 12, 2023
NEW YORK, May 1, 2023 /PRNewswire/ -- Attention Amgen Inc. ("Amgen") (NASDAQ: AMGN) shareholders:
May 01, 2023 01:45 am ET
AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amgen In
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Apr 30, 2023 05:55 pm ET
Kessler Topaz Meltzer & Check, LLP Reminds Amgen Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit
RADNOR, Pa., April 30, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ("Amgen") (NASDAQ: AMGN). The action charges Amgen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Amgen's materially misleading statements and omissions to the public, Amgen's investors
Apr 29, 2023 04:03 pm ET
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action – AMGN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the “Class Period”), of the important May 12, 2023. SO WHAT: If...
Apr 28, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DraftKings, SVB, and Amgen and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of DraftKings Inc. (NASDAQ: DKNG), SVB Financial Group (OTC: SIVPQ, SIVBQ), and...
Apr 28, 2023 06:53 pm ET
DEADLINE ALERT for AMGN, SBNY, GOOG, NSC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 28, 2023 06:34 pm ET
AMGN LAWSUIT ALERT: Levi & Korsinsky Reminds Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected...
Apr 28, 2023 05:45 am ET
AMGN SHAREHOLDER ALERT: Jakubowitz Law Reminds Amgen Shareholders of a Lead Plaintiff Deadline of May 12, 2023
NEW YORK, April 28, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN).
Apr 27, 2023 04:01 pm ET
AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif., April 27, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2023.
Apr 27, 2023 05:45 am ET
AMGN LAWSUIT ALERT: Levi & Korsinsky Notifies Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, April 27, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit.
Apr 26, 2023 08:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN
NEW YORK, April 26, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Apr 26, 2023 02:16 pm ET
AMGN ALERT: The Klein Law Firm Reminds Investors of a Lead Plaintiff Deadline of May 12, 2023 in the Class Action Filed on Behalf of Amgen Inc. Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN) alleging that the Company violated federal securities laws. This lawsuit is on behalf of all persons who purchased or...
Apr 26, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Amgen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 12, 2023 - (NASDAQ: AMGN)
NEW YORK, April 26, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Amgen Inc..
Apr 25, 2023 03:15 pm ET
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the “Class Period”), of the important May 12, 2023. SO...
Apr 25, 2023 11:15 am ET
DEADLINE ALERT for SIVBQ, AMGN, SBNY, and GOOG/GOOGL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 25, 2023 05:45 am ET
AMGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 12, 2023 in the Class Action Filed on Behalf of Amgen Inc. Shareholders
NEW YORK, April 25, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN) alleging that the Company violated federal securities laws.
Apr 24, 2023 03:01 pm ET
AMGN LAWSUIT ALERT: Levi & Korsinsky Reminds Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected...
Apr 24, 2023 11:52 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN
Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. (“Amgen” or the “Company”) (NASDAQ: AMGN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation...
Apr 24, 2023 10:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Amgen Inc. (AMGN) Investors of Class Action and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) and certain of its officers, on behalf of all persons and entities...
Apr 24, 2023 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Amgen Investors of a Lead Plaintiff Deadline of May 12, 2023
NEW YORK, April 24, 2023 /PRNewswire/ -- Attention Amgen Inc. ("Amgen") (NASDAQ: AMGN) shareholders:
Apr 24, 2023 01:45 am ET
AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amgen In
Did you lose money on investments in Amgen Inc.? If so, please visit Amgen Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
Apr 23, 2023 10:21 pm ET
AMGN Announcement: Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Amgen Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. (“Amgen”)...
Apr 23, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of SVB Financial Group (OTC: SIVPQ, SIVBQ), Amgen Inc. (NASDAQ: AMGN), and...
Apr 21, 2023 04:00 pm ET
AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif., April 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 27, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 1:30 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
Apr 21, 2023 02:22 pm ET
Kessler Topaz Meltzer & Check, LLP Reminds Amgen Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm
RADNOR, Pa., April 21, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ("Amgen") (NASDAQ: AMGN). The action charges Amgen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Amgen's materially misleading statements and omissions to the public, Amgen's investors
Apr 21, 2023 11:21 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Amgen Investors of a Lead Plaintiff Deadline of May 12, 2023
Attention Amgen Inc. ("Amgen") (NASDAQ: AMGN) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of all persons who purchased or otherwise acquired...
Apr 21, 2023 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc. (AMGN)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 12, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Amgen Inc. (“Amgen” or the “Company”)...
Apr 21, 2023 05:45 am ET
AMGN SHAREHOLDER ALERT: Jakubowitz Law Reminds Amgen Shareholders of a Lead Plaintiff Deadline of May 12, 2023
NEW YORK, April 21, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN).
Apr 20, 2023 01:40 pm ET
SHAREHOLDER ALERT: The Gross Law Firm Reminds Shareholders of Amgen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 12, 2023 – (NASDAQ: AMGN)
The Gross Law Firm issues the following notice to shareholders of Amgen Inc. Shareholders who purchased shares of AMGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as...
Apr 20, 2023 05:45 am ET
AMGN LAWSUIT ALERT: Levi & Korsinsky Notifies Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, April 20, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit.
Apr 19, 2023 06:05 pm ET
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the “Class Period”), of the important May 12, 2023. SO WHAT: If...
Apr 19, 2023 04:45 pm ET
AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST)
Appeals Court Affirms Validity of Patent Expiring in 2028
Apr 19, 2023 12:54 pm ET
AMGN ALERT: The Klein Law Firm Reminds Investors of a Lead Plaintiff Deadline of May 12, 2023 in the Class Action Filed on Behalf of Amgen Inc. Shareholders
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN) alleging that the Company violated federal securities laws. This lawsuit is on behalf of all persons who purchased or...
Apr 19, 2023 09:00 am ET
DEADLINE ALERT for AMGN, SBNY, GOOG, NSC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 19, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Amgen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 12, 2023 - (NASDAQ: AMGN)
NEW YORK, April 19, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Amgen Inc..
Apr 18, 2023 06:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN
NEW YORK, April 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Apr 18, 2023 01:50 pm ET
AMGN LAWSUIT ALERT: Levi & Korsinsky Reminds Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected...
Apr 18, 2023 12:00 pm ET
DEADLINE ALERT for SIVB, AMGN, SBNY/SBNYP, and GOOG/GOOGL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 18, 2023 05:45 am ET
AMGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 12, 2023 in the Class Action Filed on Behalf of Amgen Inc. Shareholders
NEW YORK, April 18, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN) alleging that the Company violated federal securities laws.
Apr 17, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Match, DraftKings, SVB, and Amgen and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Match Group, Inc. (NASDAQ: MTCH), DraftKings Inc. (NASDAQ: DKNG), SVB Financial...
Apr 17, 2023 10:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Amgen Inc. (AMGN) Investors of Class Action and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) and certain of its officers, on behalf of all persons and entities...
Apr 17, 2023 09:00 am ET
AMGN Investors Have Opportunity to Lead Amgen Inc. Securities Fraud Lawsuit
BENSALEM, Pa., April 17, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN).
Apr 17, 2023 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Amgen Investors of a Lead Plaintiff Deadline of May 12, 2023
NEW YORK, April 17, 2023 /PRNewswire/ -- Attention Amgen Inc. ("Amgen") (NASDAQ: AMGN) shareholders:
Apr 17, 2023 01:45 am ET
AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amgen In
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Apr 15, 2023 08:34 pm ET
Amgen Inc. Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Important Lead Plaintiff Deadline on May 12, 2023 in Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. (“Amgen”)...
Apr 14, 2023 03:14 pm ET
AMGN LAWSUIT ALERT: Levi & Korsinsky Reminds Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected...
Apr 14, 2023 05:45 am ET
AMGN SHAREHOLDER ALERT: Jakubowitz Law Reminds Amgen Shareholders of a Lead Plaintiff Deadline of May 12, 2023
NEW YORK, April 14, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN).
Apr 13, 2023 07:54 pm ET
AMGN Investors Have Opportunity to Lead Amgen Inc. Securities Fraud Lawsuit
LOS ANGELES, April 13, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN).
Apr 13, 2023 01:00 pm ET
ROSEN,A LONGSTANDING LAW FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the “Class Period”), of the important May 12, 2023. SO WHAT: If...
Apr 13, 2023 11:56 am ET
DEADLINE ALERT for SIVB, AMGN, SBNY/SBNYP, and GOOG/GOOGL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 12, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DraftKings, SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of DraftKings Inc. (NASDAQ: DKNG), SVB Financial Group (NASDAQ: SIVB, SIVBQ), Amgen...
Apr 11, 2023 04:15 pm ET
AMGN SHAREHOLDER ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the “Class Period”), of the important May 12, 2023.
Apr 11, 2023 09:25 am ET
Amgen Class Action Lawsuit Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Amgen Inc. Investors That a Securities Fraud Class Action Lawsuit Has Been Filed on Their Behalf
RADNOR, Pa., April 11, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ("Amgen") (NASDAQ: AMGN). The action charges Amgen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.  As a result of Amgen's materially misleading statements and omissions to the public, Amgen's investor
Apr 11, 2023 05:45 am ET
AMGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 12, 2023 in the Class Action Filed on Behalf of Amgen Inc. Shareholders
NEW YORK, April 11, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN) alleging that the Company violated federal securities laws.
Apr 11, 2023 01:45 am ET
AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amgen In
Did you lose money on investments in Amgen Inc.?  If so, please visit Amgen Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.                                                                                      
Apr 10, 2023 04:13 pm ET
Lowey Dannenberg Notifies Amgen, Inc. (NASDAQ: AMGN) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline
Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Amgen, Inc. (NASDAQ: AMGN) ("Amgen" or the "Company") for violations of the federal securities...
Apr 10, 2023 02:18 pm ET
AMGN LAWSUIT ALERT: Levi & Korsinsky Notifies Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected...
Apr 10, 2023 12:30 pm ET
AMGN Investors Have Opportunity to Lead Amgen Inc. Securities Fraud Lawsuit
LOS ANGELES, April 10, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN).
Apr 10, 2023 10:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Amgen Inc. (AMGN) Investors of Class Action and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) and certain of its officers, on behalf of all persons and entities...
Apr 10, 2023 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Amgen Investors of a Lead Plaintiff Deadline of May 12, 2023
NEW YORK, April 10, 2023 /PRNewswire/ -- Attention Amgen Inc. ("Amgen") (NASDAQ: AMGN) shareholders:
Apr 08, 2023 08:42 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amgen Inc. – AMGN
Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. (“Amgen” or the “Company”) (NASDAQ: AMGN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation...
Apr 08, 2023 07:00 am ET
AMGEN DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amgen To Contact Him Directly To Discuss Their Options
NEW YORK, April 8, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amgen, Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) and reminds investors of the May 12, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Apr 07, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DraftKings, SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of DraftKings Inc. (NASDAQ: DKNG), SVB Financial Group (NASDAQ: SIVB, SIVBP), Amgen...
Apr 07, 2023 12:16 pm ET
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action against Amgen Inc. and Urges Investors with Substantial Losses to Contact the Firm
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. (“Amgen”)...
Apr 07, 2023 10:30 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc. (AMGN)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 12, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Amgen Inc. (“Amgen” or the “Company”)...
Apr 06, 2023 06:15 pm ET
ROSEN, A LEADING LAW FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the “Class Period”), of the important May 12, 2023. SO WHAT: If...
Apr 06, 2023 12:00 pm ET
DEADLINE ALERT for SIVB, AMGN, SBNY/SBNYP, and GOOG/GOOGL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 05, 2023 12:37 pm ET
DEADLINE ALERT for AMGN, SBNY, GOOG, NSC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Apr 05, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Amgen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 12, 2023 - (NASDAQ: AMGN)
NEW YORK, April 5, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Amgen Inc..
Apr 04, 2023 05:38 pm ET
Amgen Inc.: Please contact the Portnoy Law Firm to recover your losses; May 2, 2023 deadline
The Portnoy Law Firm advises Amgen Inc. (NASDAQ: AMGN) investors that a lawsuit filed on behalf of investors that purchased Amgen securities (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, inclusive (the “Class Period”). Investors are...
Apr 04, 2023 05:45 am ET
AMGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 12, 2023 in the Class Action Filed on Behalf of Amgen Inc. Shareholders
NEW YORK, April 4, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN) alleging that the Company violated federal securities laws.
Apr 03, 2023 08:58 pm ET
AMGN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds AMGN Investors of Upcoming Deadline and Urges Investors with Substantial Losses to Contact the Firm
RADNOR, Pa., April 3, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ("Amgen") (NASDAQ: AMGN). The action charges Amgen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Amgen's materially misleading statements and omissions to the public, Amgen's investors
Apr 03, 2023 01:00 pm ET
AMGN LAWSUIT ALERT: Levi & Korsinsky Notifies Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected...
Apr 03, 2023 10:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Amgen Inc. (AMGN) Investors of Class Action and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) and certain of its officers, on behalf of all persons and entities...
Apr 03, 2023 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Amgen Investors of a Lead Plaintiff Deadline of May 12, 2023
NEW YORK, April 3, 2023 /PRNewswire/ -- Attention Amgen Inc. ("Amgen") (NASDAQ: AMGN) shareholders:
Apr 03, 2023 02:35 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN
NEW YORK, April 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Apr 03, 2023 01:45 am ET
AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amgen In
Did you lose money on investments in Amgen Inc.? If so, please visit Amgen Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.                                                                                      
Apr 02, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, Signature, and Norfolk Southern and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of SVB Financial Group (NASDAQ: SIVB, SIVBP), Amgen Inc. (NASDAQ: AMGN), Signature...
Mar 31, 2023 02:45 pm ET
ROSEN, A LONGSTANDING LAW FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the “Class Period”), of the important May 12, 2023. SO WHAT: If...
Mar 31, 2023 05:45 am ET
AMGN SHAREHOLDER ALERT: Jakubowitz Law Reminds Amgen Shareholders of a Lead Plaintiff Deadline of May 12, 2023
NEW YORK, March 31, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN).
Mar 30, 2023 08:36 pm ET
Amgen Equity Alert: Kessler Topaz Meltzer & Check, LLP Reminds Amgen Inc. Shareholders of Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. (“Amgen”)...
Mar 30, 2023 07:02 pm ET
Amgen Inc. (AMGN) Equity Alert: Contact Robbins LLP for Information About Your Rights Against Amgen Inc.
The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Amgen Inc. (NASDAQ: AMGN) common stock between July 29, 2020 and April 27, 2022, for...
Mar 30, 2023 11:58 am ET
DEADLINE ALERT for SIVB, AMGN, SBNY/SBNYP, and GOOG/GOOGL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 30, 2023 05:45 am ET
AMGN LAWSUIT ALERT: Levi & Korsinsky Notifies Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, March 30, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit.
Mar 29, 2023 08:44 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amgen Inc. - AMGN
Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. (“Amgen” or the “Company”) (NASDAQ: AMGN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation...
Mar 29, 2023 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Amgen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 12, 2023 - (NASDAQ: AMGN)
NEW YORK, March 29, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Amgen Inc..
Mar 28, 2023 05:45 am ET
AMGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 12, 2023 in the Class Action Filed on Behalf of Amgen Inc. Shareholders
NEW YORK, March 28, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Amgen Inc. (NASDAQ: AMGN) alleging that the Company violated federal securities laws.
Mar 27, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Match, DraftKings, SVB, and Amgen and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Match Group, Inc. (NASDAQ: MTCH), DraftKings Inc. (NASDAQ: DKNG), SVB Financial...
Mar 27, 2023 10:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Amgen Inc. (AMGN) Investors of Class Action and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) and certain of its officers, on behalf of all persons and entities...
Mar 27, 2023 09:00 am ET
AMGN Investors Have Opportunity to Lead Amgen Inc. Securities Fraud Lawsuit
BENSALEM, Pa., March 27, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN).
Mar 27, 2023 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Amgen Investors of a Lead Plaintiff Deadline of May 12, 2023
NEW YORK, March 27, 2023 /PRNewswire/ -- Attention Amgen Inc. ("Amgen") (NASDAQ: AMGN) shareholders:
Mar 27, 2023 01:45 am ET
AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amgen In
Did you lose money on investments in Amgen Inc.?  If so, please visit Amgen Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.                                                                                      
Mar 26, 2023 04:28 pm ET
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the “Class Period”), of the important May 12, 2023. SO WHAT: If...
Mar 25, 2023 08:24 pm ET
AMGN Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Amgen Inc. Investors of Securities Fraud Class Action Lawsuit
RADNOR, Pa., March 25, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ("Amgen") (NASDAQ: AMGN). The action charges Amgen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.  As a result of Amgen's materially misleading statements and omissions to the public, Amgen's investor
Mar 25, 2023 02:12 pm ET
AMGN NOTICE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Amgen Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case
SAN DIEGO, March 25, 2023 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announced that it has filed a class action lawsuit seeking to represent purchasers or acquirers of Amgen Inc. (NASDAQ: AMGN) common stock between July 29, 2020 and April 27, 2022, inclusive (the "Class Period").  Captioned Roofers Local No. 149 Pension Fund v. Amgen Inc., No. 23-cv-02138 (S.D.N.Y.), the Amgen class action lawsuit charges Amgen as well as certain of Amgen's top executives with violations of the Securities Exchange Act of 1934. 

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.